WAVE Life Sciences (NASDAQ:WVE) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of WAVE Life Sciences (NASDAQ:WVE) from a strong sell rating to a hold rating in a report released on Saturday morning.

WVE has been the subject of several other research reports. Wells Fargo & Company lowered their target price on shares of WAVE Life Sciences from $27.00 to $13.00 and set an “overweight” rating for the company in a report on Friday, March 27th. Cantor Fitzgerald raised their target price on shares of WAVE Life Sciences from $34.00 to $41.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Weiss Ratings restated a “sell (d-)” rating on shares of WAVE Life Sciences in a report on Monday, April 20th. Mizuho raised their target price on shares of WAVE Life Sciences from $22.00 to $27.00 and gave the stock an “outperform” rating in a report on Wednesday, March 25th. Finally, Wedbush raised their target price on shares of WAVE Life Sciences from $33.00 to $35.00 and gave the stock an “outperform” rating in a report on Friday, March 6th. Fourteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $27.88.

WAVE Life Sciences Stock Up 3.7%

Shares of NASDAQ:WVE opened at $7.32 on Friday. The firm has a fifty day simple moving average of $10.03 and a two-hundred day simple moving average of $11.24. The stock has a market capitalization of $1.41 billion, a P/E ratio of -6.91 and a beta of -1.32. WAVE Life Sciences has a 52 week low of $5.02 and a 52 week high of $21.73.

WAVE Life Sciences (NASDAQ:WVE) last released its earnings results on Tuesday, April 28th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.21. The firm had revenue of $38.25 million during the quarter, compared to analyst estimates of $8.45 million. WAVE Life Sciences had a negative net margin of 255.70% and a negative return on equity of 56.76%. On average, analysts expect that WAVE Life Sciences will post -1.16 earnings per share for the current year.

Insider Activity at WAVE Life Sciences

In related news, insider Chris Francis sold 33,194 shares of WAVE Life Sciences stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $15.05, for a total transaction of $499,569.70. Following the completion of the sale, the insider owned 61,867 shares in the company, valued at $931,098.35. This trade represents a 34.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Paul Bolno sold 10,480 shares of WAVE Life Sciences stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $13.45, for a total transaction of $140,956.00. Following the sale, the chief executive officer owned 275,520 shares of the company’s stock, valued at $3,705,744. The trade was a 3.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 52,373 shares of company stock worth $757,527. Corporate insiders own 23.98% of the company’s stock.

Institutional Investors Weigh In On WAVE Life Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of WAVE Life Sciences by 9.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 57,349 shares of the company’s stock valued at $463,000 after purchasing an additional 4,957 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of WAVE Life Sciences by 3.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 557,644 shares of the company’s stock valued at $4,506,000 after purchasing an additional 20,624 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of WAVE Life Sciences by 22.5% in the 2nd quarter. Rhumbline Advisers now owns 162,599 shares of the company’s stock valued at $1,057,000 after purchasing an additional 29,899 shares in the last quarter. Prudential Financial Inc. bought a new stake in shares of WAVE Life Sciences in the 2nd quarter valued at about $80,000. Finally, Norges Bank bought a new stake in shares of WAVE Life Sciences in the 2nd quarter valued at about $650,000. Institutional investors own 89.73% of the company’s stock.

Trending Headlines about WAVE Life Sciences

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: HC Wainwright nudged up EPS forecasts across multiple quarters and years (Q2–Q4 2026 and FY2026–FY2029), narrowing expected losses and reiterating a “Buy” rating with an $18 price target — a supportive signal for investors expecting improving fundamentals. MarketBeat: WAVE Life Sciences report
• Neutral Sentiment: Aggregate analyst consensus still sits at a “Moderate Buy,” indicating general optimism but not a unanimous bullish view; this consensus tempers the impact of any single firm’s outlook. WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Recommendation of “Moderate Buy” by Analysts
• Negative Sentiment: Canaccord Genuity published a pessimistic forecast for WVE’s stock price, injecting bearish sentiment that can cap upside, increase volatility, or prompt some profit-taking despite the HC Wainwright revisions. Canaccord Genuity Group Issues Pessimistic Forecast for WAVE Life Sciences (NASDAQ:WVE) Stock Price

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.